Search company, investor...

Founded Year

2016

Stage

Debt | Alive

Total Raised

$88.7M

Last Raised

$5.95M | 7 mos ago

About Redona Therapeutics

Redona Therapeutics is a biotechnology company. The company develops RNA drugs to treat cancer and other human diseases. The company's drugs are developed by researching short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation, promoting mRNA decay, and developing small molecules. The company was formerly known as TwentyEight-Seven. It was founded in 2016 and is based in Watertown, Massachusetts.

Headquarters Location

490 Arsenal Way Suite 100B

Watertown, Massachusetts, 02472,

United States

617-603-6060

Loading...

Loading...

Latest Redona Therapeutics News

Basilea’s cancer pipeline slimdown continues; Aquestive looks to outlicense seizure drug in US

Nov 2, 2022

Lei Lei Wu News Reporter In Feb­ru­ary, Swiss bio­phar­ma Basilea an­nounced an un­usu­al move — it was look­ing to ditch its on­col­o­gy as­sets in fa­vor of its in­fec­tious dis­ease pipeline. And over the past year, it has ex­e­cut­ed that plan, re­turn­ing some can­cer can­di­dates and pawn­ing off oth­ers. In its lat­est move, Basilea will be sell­ing its pre­clin­i­cal CLK ki­nase in­hibitors to Mass­a­chu­setts-based Twen­tyeight-Sev­en Ther­a­peu­tics. Twen­tyeight-Sev­en will pay Basilea CHF 1 mil­lion (rough­ly $1 mil­lion USD) up­front. Near-term mile­stones to­tal CHF 2 mil­lion, and to­tal down­stream mile­stones reach up to CHF 351 mil­lion. Twen­tyeight-Sev­en, which cur­rent­ly has a host of pre­clin­i­cal can­di­dates, was built around the idea of tar­get­ing RNA dys­reg­u­la­tion to treat can­cer. And CLK ki­nase in­hibitors go af­ter ex­act­ly that — the ab­nor­mal splic­ing of RNA in tu­mor cells. Basilea said it’s “on track to achieve sus­tain­able prof­itabil­i­ty from 2023.” Un­able to go to mar­ket, Aque­s­tive plans to out­li­cense seizure drug in US As a full FDA ap­proval on Aque­s­tive’s seizure drug Liber­vant — which is a film ver­sion of di­azepam placed in­side the cheek — re­mains up in the air, the com­pa­ny is look­ing to out­li­cense in the US, it said in its Q3 re­port Wednes­day. While the FDA grant­ed Aque­s­tive ten­ta­tive ap­proval for its ver­sion of the gener­ic for treat­ing seizures, mean­ing it’s been OK’ed on safe­ty and ef­fi­ca­cy, full ap­proval won’t come un­til Neurelis’ or­phan drug ex­clu­siv­i­ty for its nasal spray ver­sion of di­azepam, mar­ket­ed as Val­to­co, ex­pires. The ex­clu­siv­i­ty lasts for sev­en years, and the FDA ap­proved Val­to­co for seizures in 2020. Full ap­proval could come soon­er for Aque­s­tive if the FDA de­cides to re­verse its de­ci­sion, but that would re­quire ev­i­dence that Liber­vant works bet­ter than Val­to­co. Ac­cord­ing to the press re­lease, Aque­s­tive has pro­posed a head-to-head clin­i­cal study and is wait­ing for FDA feed­back. In May, Aque­s­tive re­placed long­time CEO Kei­th Kendall with COO Daniel Bar­ber. John Carroll Editor & Founder Australian pharma giant CSL is making a late bid for mRNA glory, and they’ve lined up one of the also-ran US Covid-19 biotechs touting their own particular tech twist to partner with. CSL Seqirus, the big vaccines arm of the global player, is shelling out $200 million in cash and putting up another $4.3 billion in milestones — including a hefty $1.3 billion for development goals — to ally itself with Arcturus Therapeutics. Joe Payne’s San Diego-based biotech — where Payne had to mount a counter-coup to wrest back control of the company from some rebellious board members in 2018 — is just coming off a $63 million BARDA contract, where they’re putting their mRNA tech to work on the flu. Keep reading Endpoints with a free subscription Unlock this story instantly and join 152,600+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Max Gelman Senior Editor Alkermes announced Wednesday morning it would siphon off its burgeoning oncology business, and cited one of President Joe Biden’s signature pieces of legislation as a motivator. The Irish biotech decided to spin out its cancer pipeline in order to capitalize on biologics research, execs said Wednesday, following Biden’s signing of the Inflation Reduction Act into law. With the comments, Alkermes became the third biopharma company in the last week to cite the IRA in its business and R&D decisions, following Alnylam and Eli Lilly. Keep reading Endpoints with a free subscription Unlock this story instantly and join 152,600+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor Almost half of adults with type 1 diabetes say they felt like quitting sports as a kid because of their health condition – and one in five ended up doing so. Now Dexcom wants to encourage the next generation to stick with sports, so it’s lined up a first-ever name, image, likeness (NIL) college athlete program to showcase 14 players living with type 1 diabetes. The mostly Division I men and women athletes who crisscross a range of sports — from baseball, basketball and football to cheerleading, lacrosse and swimming — all use Dexcom’s continuous glucose monitoring devices. Called Dexcom U, the program aims to bring on a new class of athletes every year who will co-create content on social media and serve as role model advocates for others living with diabetes. They’ll post about their day-to-day lives, how they train and prep for game day and how they use the Dexcom CGM to understand their diabetes state. Keep reading Endpoints with a free subscription Unlock this story instantly and join 152,600+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle LaHucik Associate Editor Surface Oncology is letting go of 20% of its workforce as the biotech prunes its pipeline and narrows the scope of its lead drug. The Boston-area cancer drug developer is looking for external partners on its CD39 asset, dubbed SRF617, after a strategic review, which the company said would extend runway into the second quarter of 2024, with burn historically being about $20 million per quarter. On the sidelines of ASCO this June, CEO Rob Ross told Endpoints News the asset was one of the biotech’s two “crown jewels” and hinted that a partner would likely be needed. But Wednesday’s news, disclosed in the quarterly update, is perhaps a little earlier than expected. Read More November 2, 2022 10:52 AM EDTUpdated 11:24 AM Amber Tong Senior Editor In the historic campaign to vaccinate the world against Covid-19, Corbevax was far from the first vaccine to reach the market. While the first mRNA shot became available 326 days after the SARS-CoV-2 virus was sequenced, the journey of Corbevax — which has so far gone into the arms of 75 million kids in India and recently won approval for adults — spanned about 600 days. But Peter Hotez, one of its co-inventors, believes it could’ve played out differently if his team had received more funding and there was a smoother regulatory path. “That could have been probably cut in half had we had the support to move faster,” said Hotez, the co-director of the Texas Children’s Hospital Center for Vaccine Development. There was good reason to go faster. The mad scramble for life-saving shots exposed the stark disparities between the vaccine haves and have-nots. Corbevax, a patent-free vaccine based on older but proven technology, can be affordably produced and distributed to lower-income countries. The Corbevax story is relevant to a bigger question as the world attempts to strengthen vaccine research and development infrastructure to go even faster and more equitably distribute vaccines. Vexing scientific, regulatory and manufacturing challenges must be solved ahead of the next pandemic, public health experts and advocacy group representatives said in interviews. The Coalition for Epidemic Preparedness Innovations, or CEPI, which launched in 2017 in the wake of the Ebola outbreak in West Africa, has proposed what it calls a moonshot goal of spurring a vaccine against a new pandemic-causing pathogen in 100 days. The initiative is known as the 100 Days Mission. Melanie Saville, CEPI’s executive director of vaccine R&D, reckons the group would’ve been “laughed out of the room” if they had told people before the Covid-19 pandemic that a vaccine would arrive within 326 days – but already there’s a path to going faster. “If you actually put everybody’s innovation together from Covid-19, we already probably could shave off two months by looking meticulously at every step of the process,” she said, citing a CEPI analysis based on interviews with companies, international organizations, regulatory agencies, academia and the media. To get to 100 days, though, much more needs to be done. The key is to do as much of it upfront as possible, she added, during so-called peacetime, much like decades-long RNA research ushered in the first Covid-19 vaccines. Premium subscription required

Redona Therapeutics Frequently Asked Questions (FAQ)

  • When was Redona Therapeutics founded?

    Redona Therapeutics was founded in 2016.

  • Where is Redona Therapeutics's headquarters?

    Redona Therapeutics's headquarters is located at 490 Arsenal Way, Watertown.

  • What is Redona Therapeutics's latest funding round?

    Redona Therapeutics's latest funding round is Debt.

  • How much did Redona Therapeutics raise?

    Redona Therapeutics raised a total of $88.7M.

  • Who are the investors of Redona Therapeutics?

    Investors of Redona Therapeutics include Osage University Partners, Sofinnova Partners, MPM Capital, Vertex Ventures HC, Novartis Venture Funds and 6 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.